Refine by
Vascular Blood Articles & Analysis
18 news found
He also developed what was likely the first vascular clamp. Ligation of blood vessels with various suture materials permitted the development of modern surgery. ...
Already in the first stages of the disease, patients are affected by episodes of reduced blood flow in fingers and toes. The episodes, known as Raynaud's phenomenon, are often followed by very painful and difficult-to-heal digital ulcers (ulcers of the fingers and toes). ...
Already at an early stage of the disease, patients suffer from episodes of impaired blood flow in the fingers and toes, Raynaud's phenomenon, which in the course of the disease often lead to very painful, difficult-to-heal, and frequently disabling ulcers. ...
The study investigates the safety of GS-248 and its efficacy on Raynaud's phenomenon and peripheral vascular blood flow. Top-line data is expected in Q1/2022. Coordinating Investigator Professor Ariane Herrick, The University of Manchester Centre for Musculoskeletal Research commented: "Systemic sclerosis is a chronic, autoimmune disease that leads to ...
Healionics is preparing to commercialize its innovative STARgraft vascular graft, designed to provide a safer and more reliable means to access the bloodstream for dialysis in patients with kidney failure. ...
Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embolotherapy, today announced the enrollment of the first patients in the Embrace Hydrogel Embolic System (HES™) global randomized clinical trial for the treatment of hypervascular tumors. ...
In the first stage, attacks of reduced blood flow to the fingers and toes (Raynaud's phenomenon) occur, which causes pain and impaired fine motor skills. ...
Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice. ...
Vascular access technology pioneer Velano Vascular this past week made its new streamlined remote training program widely available for hospitals around the nation. Initially developed with existing partners utilizing its PIVO™ needle-free blood draw device in the fight against COVID-19, the platform is now available for additional ...
The Cellvizio®100 series system with all its different Confocal Miniprobes™ is now cleared for use with the fluorescein dye to image blood flow in the microvasculature and capillaries Mauna Kea Technologies today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Cellvizio® 100 series and all associated Confocal ...
“We are thrilled to welcome new and returning investors as we continue to establish a more humane global standard for hospital practice at the intersection of blood collection, vascular access, and infection prevention,” said Velano Chief Executive Eric M. ...
Food and Drug Administration (FDA) and initial launch of the LOBO™ Vascular Occlusion System. The Company further announced that U.S. Patent No. 10,376,267, entitled Vascular Occlusion Device and Methods, has been issued by the United States Patent and Trademark Office. ...
The financing supports the first human study, currently underway, of the company's innovative STARgraft vascular graft. In preclinical studies, STARgraft demonstrated improved ability to maintain blood flow compared to on-market vascular grafts, thereby offering the potential to reduce cost and morbidity while improving quality of life among ...
” Said Takeuchi, “Healionics’ STARgraft and related future products have the potential to reduce the huge costs associated with maintaining reliable vascular access for dialysis patients and to improve the health and quality of life of these patients. ...
The clinical study will evaluate STARgraft as a vascular access graft for dialysis patients and will be conducted in collaboration with University of Washington Medicine. In the United States, more than 470,000 patients with kidney failure rely on thrice-weekly hemodialysis treatment to survive. Maintaining a reliable vascular access site for these patients is ...
The company’s BioMimics 3D technology is based on research by Professor Colin Caro into the link between blood flow mechanics and vascular disease. Innovations first invested in Veryan in 2004 and as at 31 January 2014, the company held a 44.3% stake, with a carrying value of £16.97m (on £9.83m invested by Innovations). ...
About diabetes in the elderly Type 2 diabetes is one of the most common chronic disorders in older adults, with a prevalence of approximately 20 percent in people older than 65 years[7]. Controlling blood sugar in elderly patients with type 2 diabetes is challenging due to higher rates of comorbidities, a higher burden of physical disability, cognitive impairment and frailty, an ...
When compared with monotherapy, the combination therapy increased densities of key blood vessels, arteries, and smooth muscle cells in vascular walls. ...